REGENXBIO Inc.
RGNXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How REGENXBIO Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 13 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 2, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Farther Finance Advisors, LLC | 2026-03-31 | 368 | $3.18K | SEC filing |
| GROUP ONE TRADING LLC | 2026-03-31 | 1,678 | $14.1K | SEC filing |
| Pallas Capital Advisors LLC | 2026-03-31 | 13,119 | $110K | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 554,892 | $4.65M | SEC filing |
| Centiva Capital, LP | 2026-03-31 | 100,000 | $838K | SEC filing |
| Connor, Clark & Lunn Investment Management Ltd. | 2026-03-31 | 85,248 | $714K | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 244 | $2.05K | SEC filing |
| D. E. Shaw & Co., Inc. | 2026-03-31 | 286,001 | $2.4M | SEC filing |
| Essential Partners LLC | 2026-03-31 | 2,096 | $17.6K | SEC filing |
| Point72 Asset Management, L.P. | 2026-03-31 | 139,791 | $1.17M | SEC filing |
| DEUTSCHE BANK AG\ | 2026-03-31 | 196,971 | $1.65M | SEC filing |
| STIFEL FINANCIAL CORP | 2026-03-31 | 392,769 | $3.29M | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 200,352 | $1.68M | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 390,601 | $3.27M | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 244 | $2.05K | SEC filing |
| Hudson Bay Capital Management LP | 2026-03-31 | 180,000 | $1.51M | SEC filing |
| 22NW, LP | 2026-03-31 | 492,759 | $4.13M | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 8,983 | $75.3K | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 1,310,493 | $11M | SEC filing |
| Fortitude Family Office, LLC | 2026-03-31 | 58 | $486 | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among REGENXBIO Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-10-09 · Simpson Curran: Larger than 33 of the 35 other insider sales of Common Stock on file. SEC filing
- 2025-05-12 · Mills Kenneth T.: Larger than 32 of the 35 other insider sales of Common Stock on file. SEC filing
- 2024-01-16 · Mills Kenneth T.: Larger than 34 of the 35 other insider sales of Common Stock on file. SEC filing
- 2023-12-19 · Mills Kenneth T.: Larger than 34 of the 35 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-11 | PAKOLA STEVE · Chief Medical Officer | Common Stock | S — Open market or private sale | −15,309 | 11.02 | SEC filing |
| 2026-03-10 | PAKOLA STEVE · Chief Medical Officer | Common Stock | S — Open market or private sale | −5,124 | 10.35 | SEC filing |
| 2025-10-09 | Simpson Curran · Chief Executive Officer | Common Stock | S — Open market or private sale | −20,811 | 12.62 | SEC filing |
| 2025-09-29 | Simpson Curran · Chief Executive Officer | Common Stock | S — Open market or private sale | −7,624 | 10.03 | SEC filing |
| 2025-09-10 | Simpson Curran · Chief Executive Officer | Common Stock | S — Open market or private sale | −7,734 | 10.02 | SEC filing |
| 2025-05-12 | Mills Kenneth T. · Director | Common Stock | S — Open market or private sale | −20,602 | 7.91 | SEC filing |
| 2024-10-01 | KARABELAS ARGERIS N · Director | Common Stock | S — Open market or private sale | −10,000 | 10.11 | SEC filing |
| 2024-09-03 | KARABELAS ARGERIS N · Director | Common Stock | S — Open market or private sale | −9,300 | 11.50 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-29 | Fox Allan M. · Director | Common Stock | A — Grant, award, or other acquisition | +9,807 | SEC filing |
| 2026-05-29 | Fox Allan M. · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +46,600 | SEC filing |
| 2026-05-29 | STUMP DAVID C · Director | Common Stock | A — Grant, award, or other acquisition | +9,807 | SEC filing |
| 2026-05-29 | Mills Kenneth T. · Director | Common Stock | A — Grant, award, or other acquisition | +9,807 | SEC filing |
| 2026-05-29 | Bennett Jean · Director | Common Stock | A — Grant, award, or other acquisition | +9,807 | SEC filing |
| 2026-05-29 | MIGAUSKY GEORGE V · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +46,600 | SEC filing |
| 2026-05-29 | Mills Kenneth T. · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +46,600 | SEC filing |
| 2026-05-29 | KARABELAS ARGERIS N · Director | Common Stock | A — Grant, award, or other acquisition | +9,807 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.